Profound Medical Corp.

TSX:PRN.TO

Medical - Devices

Healthcare
$9.83 +1.18%

+$0.11 today

Market cap
$360.04M
Beta
0.52
P/E (TTM)
-6.3
EPS (TTM)
-$1.07
52W Low $5.23High $12.40

Volume 0.00M

Average 0.01M

PRN.TO Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Profound Medical Corp.TSX: PRN.TO

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation grows, but more slowly than its trailing trend

Q1 FY2026 stock-based compensation of $1.05M rose 6.0% year over year, behind the +98.0% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 24.1% from the prior quarter. Over 3 fiscal years it compounded at +9.0% a year.

Context

  • Stock-based compensation amounted to 33.5% of revenue in FY2025, up 9.4 pp from a year earlier.
  • Stock-based compensation increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +6.0% toward the trailing-twelve-month pace of +98.0%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.05M-24.1% QoQ
Last fiscal yearDec 2025
$5.49M+112.7% YoY
LTMMar 2026
$5.55M+98.0% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+6.0%——
1 year+112.7%——
3-year CAGR+9.0%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
5.49M USD
Year-over-year change
+112.7%
4-year CAGR
-6.6%

Stock-Based Compensation vs competitors

How PRN.TO compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +98.0% is the 3rd highest of 6, against a peer median of +5.0%.
  • Stock-based compensation amounts to 29.6% of revenue for PRN.TO, versus a peer median of 1.6%.
PRN.TO Competitors
Stock-Based Compensation for PRN.TO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
EPRX.TOEupraxia Pharmaceuticals Inc.LTM Mar 2026$9.67M USD+143.3%+84.7%—
PRN.TOProfound Medical Corp.LTM Mar 2026$5.55M USD+98.0%+9.0%29.6%
XLY.TOAuxly Cannabis Group Inc.LTM Mar 2026CA$4.81M CAD+5.0%+9.4%3.0%
CRRX.TOCareRx CorporationLTM Mar 2026CA$2.25M CAD-37.4%-15.9%0.6%
HLS.TOHLS Therapeutics Inc.LTM Mar 2026$1.4M USD-30.3%-13.2%2.5%
DR.TOMedical Facilities CorporationLTM Mar 2026$246K USD+228.0%—0.1%
Peer median (excluding PRN.TO) —+5.0%-1.9%1.6%

Competitors are the stored peer set for PRN.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(30.7M)(28.67M)(28.32M)(27.82M)(42.57M)
Depreciation & Amortization1.88M1.6M1.15M936K569.8K
Deferred Income Tax(293K)0232K00
Stock-Based Compensation7.21M4.24M3.42M2.58M5.49M
Change in Working Capital(877K)(5.63M)540K591K(1.74M)
Accounts Receivables2M(1.93M)(1.41M)186K(175.01K)
Inventory(2.49M)(1.86M)353K656K(2.87M)
Accounts Payables(356K)(566K)1.36M815K384.62K
Other Working Capital(26K)(1.27M)244K(1.07M)918.81K
Other Non-Cash Items425K2.66M379K255K(622.65K)
Operating Cash Flow(22.36M)(25.8M)(22.61M)(23.45M)(38.88M)
Capital Expenditures(593K)000(179.08K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow(583.04K)000(246.24K)
Debt Repayment(386K)6.92M(1.2M)(2.56M)(1.33M)
Common Stock Issued6.32M255.17K2.71M62.11M43.19M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities9.03K(141.17K)248.74K(4.85M)0
Financing Cash Flow5.95M7.03M1.76M54.7M41.86M
Effect of Forex Changes244K(1.87M)549K(2.54M)(630.95K)
Net Change in Cash(16.76M)(20.64M)(20.3M)28.7M2.11M
Free Cash Flow(22.95M)(25.8M)(22.3M)(23.45M)(39.05M)

Profound Medical Corp.

TSX:PRN.TO

Intrinsic Alpha fair value

Locked

Current Price

$9.83

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.